In vitro-in vivo characterization of release modifying agents for parenteral sustained-release ketorolac formulation

Drug Development and Industrial Pharmacy

Volumn 30, Issue 6, 2004, Pages 619-626

  Puri, V ^a   Bansal, A K ^a  

^a NATIONAL INSTITUTE OF PHARMACEUTICAL EDUCATION AND RESEARCH NIPER   (India)

Author keywords

Biocompatible; Biodegradable; Ketorolac

Indexed keywords

GLYCEROL OLEATE; KETOROLAC; KETOROLAC TROMETAMOL; POVIDONE;

ANALGESIC ACTIVITY; ANIMAL EXPERIMENT; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CONTROLLED STUDY; DOSE TIME EFFECT RELATION; DRUG BLOOD LEVEL; MALE; MOUSE; NONHUMAN; SUSTAINED RELEASE PREPARATION; WRITHING TEST;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CASTOR OIL; CHEMISTRY, PHARMACEUTICAL; DELAYED-ACTION PREPARATIONS; EXCIPIENTS; GLYCERIDES; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; KETOROLAC TROMETHAMINE; MALE; MICE; PAIN MEASUREMENT; PHARMACEUTIC AIDS; POVIDONE; SOLUBILITY; TIME FACTORS;

EID: 3142663192     PISSN: 03639045     EISSN: None     Source Type: Journal    
DOI: 10.1081/DDC-120037608     Document Type: Article

References (20)

1. Dahl, J.B.; Kehlet, H. Non-steroidal anti-inflammatory drugs: rationale for use in severe postoperative pain. Br. J. Pharmacol. 1991, 66, 703-712.
2. Dahl, J.B. Postoperative analgesia; review. Acta Anaesthesiol. Scand. 2000, 44, 1-13.
3. Gillis, J.C.; Brogden, R.N. Ketorolac: a reappraisal of its pharmacodynamic and pharmacokinetic properties and therapeutic use in pain management. Drugs 1997, 53, 139-188.
4. DeAndrade, J.R.; Maslanka, M.; Maneatis, T.; Bynum, L.; Burchmore, M. The use of ketorolac in the managment of postoperative pain. Orthopedics 1994, 17, 157-166.
5. Domer, F. Characterization of the analgesic activity of ketorolac in mice. Eur. J. Pharmacol. 1990, 177, 127-135.
6. United States Pharmacopeia 24/ National Formulary 19. United States Pharmacopeial Convention, Rockville, MD, 1999; 946.
7. Mroszczak, E.J.; Lee, F.W.; Combs, D.; Sarquist, F.H.; Huang, B.L. Ketorolac tromethamine absorption, distribution, metabolism, excretion, and pharmacokinetics in animal and humans. Drug Metab. Dispos. 1987, 15, 618-626.
8. Loftsson, T.; Fridriksdottir, H.; Gudmundsdottir, T.K. The effect of water-soluble polymers on aqueous solubility of drugs. Int. J. Pharm. 1996, 127, 293-296.
9. URL:http://www.basf.de/en/dispersionen/products/ pvp (accessed June 2000).
10. Malhotra, M.; Majumdar, D.K. In vitro transcorneal permeation from oil based ocular drops and ophthalmic ointment. Indian J. Exp. Biol. 1997, 35, 1324-1330.
11. Chang; Hung-Chih; Li; Lukchiu; Tian; Youqin. Butorphanol sustained release formulations. Unites States Patent 6,197,344, March 6, 2001.
12. Engstrom, S.; Lindahl, L.; Wallin, R.; Engblom, J. A study of polar lipid drug carrier systems undergoing a thermoreversible lamellar-to-cubic phase transition. Int. J. Pharm. 1992, 86, 137-145.
13. Wyatt, D.M. A cubic-phase delivery system composed of glyceryl monooleate and water for sustained release of Water-soluble drugs. Pharm. Technol. 1992, 16, 116-122.
14. Shah, J.C.; Sadhale, Y.; Chilukuri, D.M. Cubic phase gels as drug delivery systems. Adv. Drug Deliv. Rev. 2001, 47, 229-250.
15. Malonne, H.; Fontaine, J.; Moes, A. In vitro/in vivo characterisation of a Tramadol HCl depot system composed of monoolein and water. Biol. Pharm. Bull. 2000, 23, 627-631.
16. Vogel, H.G.; Vogel, W.H. Analgesia, antiinflammatory and antipyretic activity. In Drug Discovery and Evaluation; Springer, 1997; 360-420.
17. Benita, S.; Friedman, D.; Weinstock, M. Pharmacological evaluation of an injectable prolonged release emulsion of physostigmine in rabbits. J. Pharm. Pharmacol. 1986, 38, 653.
18. Toradol® IV/IM Complete Product Information; Roche U.S. Pharmaceuticals, 2002.
19. Ritschel, W.A. Biopharmaceutic and pharmacokinetic aspects in the design of controlled release peroral drug delivery systems. Drug Dev. Ind. Pharm. 1989, 15, 1073-1103.
20. Steinijans, V.W. Pharmacokinetic characterisation of controlled-release formulations. Eur. J. Drug Metab. Pharmacokinet. 1990, 15, 173-181.